

Clark (MA) Hudson  
 Clarke (NY) Huffman  
 Clay Huiזנגa  
 Cleaver Hurd (TX)  
 Cline Jackson Lee  
 Cloud Jayapal  
 Clyburn Jeffries  
 Cohen Johnson (GA)  
 Cole Johnson (LA)  
 Collins (GA) Johnson (OH)  
 Conaway Johnson (SD)  
 Connolly Johnson (TX)  
 Cook Joyce (OH)  
 Cooper Kaptur  
 Correa Katko  
 Costa Keating  
 Courtney Keller  
 Cox (CA) Kelly (IL)  
 Craig Kelly (PA)  
 Crawford Kennedy  
 Crenshaw Khanna  
 Crist Kildee  
 Crow Kilmer  
 Cuellar Kim  
 Cunningham Kind  
 Curtis King (NY)  
 Davids (KS) Kinzinger  
 Davis (CA) Kirkpatrick  
 Davis, Danny K. Krishnamoorthi  
 Davis, Rodney Kuster (NH)  
 Dean Kustoff (TN)  
 DeFazio LaHood  
 DeGette LaMalfa  
 DeLauro Lamb  
 DelBene Lamborn  
 Delgado Langevin  
 Demings Larsen (WA)  
 DeSaulnier Larson (CT)  
 Deutch Latta  
 Diaz-Balart Lawrence  
 Dingell Lee (CA)  
 Doggett Lee (NV)  
 Doyle, Michael Levin (CA)  
 F. Levin (MI)  
 Emmer Lewis  
 Engel Lieu, Ted  
 Escobar Lipinski  
 Eshoo Loeb sack  
 Espaillat Lofgren  
 Evans Lowenthal  
 Ferguson Lowey  
 Finkenauer Lucas  
 Fitzpatrick Lujan  
 Fletcher Luria  
 Flores Lynch  
 Fortenberry Malinowski  
 Foster Maloney,  
 Foxx (NC) Carolyn B.  
 Frankel Maloney, Sean  
 Fudge Marchant  
 Gallagher Matsui  
 Gallego McAdams  
 Garamendi McBath  
 Garcia (IL) McCarthy  
 Garcia (TX) McCaul  
 Gianforte McCollum  
 Golden McGovern  
 Gomez McHenry  
 Gonzalez (OH) McKinley  
 Gonzalez (TX) McNerney  
 Gottheimer Meeks  
 Granger Meng  
 Graves (LA) Mitchell  
 Graves (MO) Moolenaar  
 Green (TN) Moore  
 Green, Al (TX) Morelle  
 Griffith Moulton  
 Grijalva Mucarsel-Powell  
 Grothman Murphy (FL)  
 Guthrie Nadler  
 Haaland Napolitano  
 Hagedorn Neal  
 Harder (CA) Neguse  
 Hartzler Newhouse  
 Hastings Norcross  
 Hayes Nunes  
 Heck O'Halleran  
 Hern, Kevin Ocasio-Cortez  
 Herrera Beutler Olson  
 Higgins (LA) Pallone  
 Higgins (NY) Palmer  
 Hill (AR) Panetta  
 Hill (CA) Pappas  
 Himes Pascrell  
 Holding Payne  
 Horn, Kendra S. Perlmutter  
 Horsford Perry  
 Houlahan Peters  
 Hoyer Phillips

Pingree  
 Pocan  
 Porter  
 Pressley  
 Price (NC)  
 Quigley  
 Raskin  
 Ratcliffe  
 Reschenthaler  
 Rice (NY)  
 Richmond  
 Riggelman  
 Roby  
 Rodgers (WA)  
 Roe, David P.  
 Rogers (AL)  
 Rogers (KY)  
 Rose (NY)  
 Rouda  
 Rouzer  
 Roybal  
 Royal-Ballard  
 Ruiz  
 Ruppersberger  
 Sánchez  
 Sarbanes  
 Scalise  
 Scanlon  
 Schakowsky  
 Schiff  
 Schneider  
 Schrader  
 Schrier  
 Schweikert  
 Scott (VA)  
 Scott, Austin  
 Scott, David  
 Sensenbrenner  
 Serrano  
 Sewell (AL)  
 Shalala  
 Sherman  
 Sherrill  
 Shimkus  
 Simpson  
 Sires  
 Slotkin  
 Smith (NE)  
 Smith (NJ)  
 Smith (WA)  
 Smucker  
 Soto  
 Spanberger  
 Spano  
 Stanton  
 Stauber  
 Stefanik  
 Steil  
 Stevens  
 Stewart  
 Stivers  
 Suozzi  
 Swalwell (CA)  
 Takano  
 Taylor  
 Thompson (CA)  
 Thompson (MS)  
 Thompson (PA)  
 Thornberry  
 Timmons  
 Tipton  
 Titus  
 Tlaib  
 Tonko  
 Torres (CA)  
 Torres Small  
 (NM)  
 Trahan  
 Trone  
 Turner  
 Underwood  
 Upton  
 Van Drew  
 Vargas  
 Veasey  
 Vela  
 Velázquez  
 Visclosky  
 Wagner  
 Walden  
 Walker  
 Walorski  
 Waltz  
 Wasserman  
 Schultz  
 Waters  
 Watson Coleman  
 Welch  
 Wenstrup  
 Westerman

Wexton  
 Wild  
 Wilson (FL)  
 Wilson (SC)  
 Wittman  
 Womack  
 Woodall  
 Wright  
 Yarmuth  
 Young  
 Zeldin

(H.R. 3889) to amend the Office of National Drug Control Policy Reauthorization Act of 1998 to make technical corrections, as amended.  
 The Clerk read the title of the bill.  
 The text of the bill is as follows:  
 H.R. 3889  
*Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,*  
**SECTION 1. SHORT TITLE.**  
 This Act may be cited as the “ONDCP Technical Corrections Act of 2019”.  
**SEC. 2. TECHNICAL CORRECTIONS.**  
 (a) OFFICE OF NATIONAL DRUG CONTROL POLICY REAUTHORIZATION ACT OF 1998 TECHNICAL CORRECTIONS.—The Office of National Drug Control Policy Reauthorization Act of 1998 (21 U.S.C. 1701 et seq.) is amended—  
 (1) by striking “National Drug Control Program Agency” and inserting “National Drug Control Program agency” each place it appears;  
 (2) by striking “National Drug Control Program Agencies” and inserting “National Drug Control Program agencies” each place it appears;  
 (3) in section 702(15), by striking “tribal” each place it appears and inserting “Tribal”;  
 (4) in section 703—  
 (A) in subsection (a)—  
 (i) in paragraph (4), by striking “program,” and inserting “programs,”; and  
 (ii) in paragraph (6), by striking “High-Intensity” and inserting “High Intensity”; and  
 (B) in subsection (d), by striking “chapter” each place it appears and inserting “title”;  
 (5) in section 704—  
 (A) in subsection (a)(1)—  
 (i) in subparagraph (C)—  
 (I) in clause (i), by striking “section 704(c)(4)” and inserting “subsection (c)(5)”; and  
 (II) in clause (iv), by striking “section 704(j)” and inserting “subsection (j)”; and  
 (ii) in subparagraph (D)—  
 (I) by striking “The Director shall determine whether the coordinator position is a noncareer” and inserting “For purposes of carrying out the previous sentence, the Director shall designate or appoint an”; and  
 (II) by striking “a career” and inserting “an”;  
 (B) in subsection (b)(21)(A)(iii), by striking “chapter” and inserting “title”;  
 (C) in subsection (c)—  
 (i) in paragraph (2)(A)(ii), by striking “fo” and inserting “of”;  
 (ii) in paragraph (3)(E)(ii)—  
 (I) in subclause (I), by striking “subparagraph (A)” and inserting “clause (i)”; and  
 (II) in subclause (II), by striking “clause (i)” and inserting “subclause (I)”; and  
 (iii) in paragraph (5)(B)—  
 (I) by striking “The Director shall determine whether the coordinator position is a noncareer” and inserting “For purposes of carrying out subparagraph (A), the Director shall designate or appoint an”; and  
 (II) by striking “a career” and inserting “an”;  
 (D) in subsection (d)—  
 (i) paragraph (8)—  
 (I) in subparagraph (E)—  
 (aa) in clause (iii), by moving subclauses (I) through (V) two ems to the left so that the left margin of such clause is aligned with the margin of clause (iii);  
 (bb) by moving clause (iii) two ems to the left so that the left margin of such clause is aligned with the margin of subparagraph (E); and  
 (cc) by redesignating clause (iii) as subparagraph (F); and  
 (II) in subparagraph (F), as so redesignated—

NAYS—60

ANSWERED “PRESENT”—4

NOT VOTING—14

□ 1444

Mr. LONG changed his vote from “yea” to “nay.”

Mr. GOSAR changed his vote from “present” to “nay.”

So (two-thirds being in the affirmative) the rules were suspended and the joint resolution was passed.

The result of the vote was announced as above recorded.

A motion to reconsider was laid on the table.

Stated for:

Ms. SPEIER. Mr. Speaker, I was in the Rayburn room meeting with constituents and was not alerted to the vote being called. Had I been present, I would have voted “yea” on rollcall No. 560.

Mr. PETERSON. Mr. Speaker, it was my intention to vote yea on Representative ELIOT ENGEL of New York’s House Joint Resolution 77 (Roll Call Vote no. 560) on October 16, 2019.

PERSONAL EXPLANATION

Mr. BUDD. Mr. Speaker, I missed votes today to attend the funeral of a family friend. Had I been present, I would have voted “nay” on rollcall No. 558, “nay” on rollcall No. 559 and “nay” on rollcall No. 560.

ANNOUNCEMENT BY THE SPEAKER PRO TEMPORE

The SPEAKER pro tempore. Pursuant to clause 8 of rule XX, the Chair will postpone further proceedings today on the additional motions to suspend the rules on which a recorded vote or the yeas and nays are ordered, or on which the vote is objected to under clause 6 of rule XX.

Any recorded vote on the postponed question will be taken later.

ONDCP TECHNICAL CORRECTIONS ACT OF 2019

Mr. ROUDA. Mr. Speaker, I move to suspend the rules and pass the bill

(aa) by redesignating subclauses (I) through (V) as clauses (i) through (v), respectively; and

(bb) in clause (v), as so redesignated, by striking the period at the end and inserting a semicolon; and

(ii) in paragraph (9), by striking “section 704(f)(5);” and inserting “subsection (f)(5); and”;

(E) in subsection (j)—

(i) by striking “The Director shall determine whether the coordinator position is a noncareer” and inserting “For purposes of carrying out the previous sentence, the Director shall designate or appoint an”;

(ii) by striking “a career” and inserting “an”;

(iii) by inserting “section” before “706”;

(6) in section 705—

(A) in subsection (d)(1), by striking “that every” and inserting “than every”; and

(B) in subsection (f)—

(i) in paragraph (1)—

(I) in subparagraph (A)(i), by striking the semicolon at the end and inserting “; and”;

(II) in subparagraph (C)—

(aa) by inserting “that may impede applicants” after “barriers”; and

(bb) by striking “impediments” and all that follows through “agencies”; and

(ii) in paragraph (2), in the heading, by striking “DRUG CONTROL” and inserting “DRUG CONTROL PROGRAM”;

(7) in section 707(o)(2)(B), by striking “802(33)” and inserting “802(33)”; and

(8) in section 709—

(A) in subsection (a)—

(i) in the heading, by inserting “AND CONTINUING” before “THREATS”;

(ii) by striking “The Director shall determine whether the coordinator position is a noncareer” and inserting “For purposes of carrying out the previous sentence, the Director shall designate or appoint an”;

(iii) by striking “a career” and inserting “an”;

(B) in subsection (d)—

(i) in paragraph (3)(F), by striking “response of” and inserting “response to”;

(ii) in paragraph (4)(B)(iii), by inserting “the” before “plan, where”;

(C) in subsection (f)(1), by striking “sub-title” and inserting “subsection”.

(b) REPEAL OF ANNUAL REPORT REQUIREMENT.—The Office of National Drug Control Policy Reauthorization Act of 2006 (Public Law 109-469; 120 Stat. 3502) is amended—

(1) by repealing section 203; and

(2) in section 1(c), in the table of contents, by striking the item relating to section 203.

(c) TECHNICAL CORRECTION TO THE SUBSTANCE ABUSE PREVENTION ACT OF 2018.—

(1) AMENDMENTS.—The Substance Abuse Prevention Act of 2018 (subtitle K of title VIII of Public Law 115-271) is amended—

(A) in section 8203—

(i) in subsection (a)—

(I) in the heading, by striking “NATIONAL NARCOTICS LEADERSHIP ACT OF 1988” and inserting “ANTI-DRUG ABUSE ACT OF 1988”;

(II) in paragraph (1), by striking “the National Narcotics Leadership Act of 1988” and inserting “subtitle A of title I of the Anti-Drug Abuse Act of 1988”;

(III) by striking paragraph (3);

(IV) by redesignating paragraph (4) as paragraph (3); and

(V) in paragraph (3)(A), as so redesignated, by striking “National Narcotics Leadership Act of 1988” and inserting “Anti-Drug Abuse Act of 1988”;

(ii) in subsection (b)—

(I) in the heading, by striking “NATIONAL NARCOTICS LEADERSHIP ACT OF 1988” and inserting “ANTI-DRUG ABUSE ACT OF 1988”;

(II) in the matter preceding paragraph (1), by striking “National Narcotics Leadership

Act of 1988” and inserting “Anti-Drug Abuse Act of 1988”;

(III) in paragraph (4)(B), by striking “in section 1032(b)(1)(A) (21 U.S.C. 1532(b)(1)(A)), by striking clause (iii) and inserting the following” and inserting “by amending section 1032(b)(3)(D) (21 U.S.C. 1532(b)(3)(D)) to read as follows”;

(iii) in the quoted matter added by subsection (b)(4)(B)—

(I) in clause (iii), by moving subclauses (I) and (II) two ems to the left so that the left margins of such subclauses are aligned with the margin of clause (iii);

(II) by moving clause (iii) two ems to the left so that the left margin of such clause is aligned with the margin of subparagraph (B) of subsection (b)(4);

(III) by redesignating clause (iii) as subparagraph (D); and

(IV) in subparagraph (D), as so redesignated—

(aa) by redesignating subclauses (I) and (II) as clauses (i) and (ii), respectively; and

(bb) in clause (ii), as so redesignated, by striking “tears” and inserting “years”; and

(B) in section 8221—

(i) in the quoted matter added by subsection (a), by striking “SEC. 706. NATIONAL DRUG CONTROL STRATEGY.”; and

(ii) in subsection (a), by striking “amended to read as follows:” and inserting “amended—

“(1) by striking subsections (a) and (b);

“(2) by redesignating subsections (c) and (d) as subsections (h) and (i), respectively; and

“(3) by inserting before subsection (h), as so redesignated, the following:”.

(2) EFFECTIVE DATE.—The amendments made by this subsection shall take effect as if included in the enactment of the Substance Abuse Prevention Act of 2018 (subtitle K of title VIII of Public Law 115-271).

(3) MATCHING REQUIREMENT REVIVED AND RESTORED.—Section 1032(b)(1)(A)(iii) of the Anti-Drug Abuse Act of 1988 (21 U.S.C. 1532(b)(1)(A)) is revived and restored as if the amendment made by section 8203(b)(4) of the Substance Abuse Prevention Act of 2018 (subtitle K of title VIII of Public Law 115-271) had never been enacted.

(4) ADDITIONAL TECHNICAL CORRECTIONS TO THE OFFICE OF NATIONAL DRUG CONTROL POLICY REAUTHORIZATION ACT OF 1998.—Section 706 of the Office of National Drug Control Policy Reauthorization Act of 1998 (21 U.S.C. 1701 et seq.) is amended—

(1) in subsection (c)(1)(N)—

(A) in clause (ii), by striking “Programs” and inserting “Program agencies”; and

(B) in clause (iii), by striking “Agencies” and inserting “Program agencies”;

(2) in subsection (c)(2), in the matter preceding subparagraph (A), by striking “paragraph (1)” and inserting “paragraph (1)(M)”;

(3) in subsection (f)—

(A) in paragraph (2), by striking “office” and inserting “Office”; and

(B) in paragraph (3)(A)(ii)—

(i) in subclause (III), by striking the semicolon at the end and inserting “; and”;

(ii) in subclause (IV), by striking the semicolon at the end and inserting a period; and

(4) in subsection (g)(3), in subparagraph (B), by striking “chapter;” and inserting “title;”.

(e) ADMINISTRATION OF GRANT.—Section 4 of Public Law 107-82 (21 U.S.C. 1521 note) is amended—

(1) in subsection (a)—

(A) by striking “The Director” and inserting “Beginning in fiscal year 2020, the Director”;

(B) by striking “, using amounts authorized to be appropriated by subsection (d),”;

and

(2) by amending subsection (d) to read as follows:

“(d) ADMINISTRATION OF GRANT.—

“(1) DURATION.—With respect to a grant made under subsection (a) in fiscal year 2020, the term of the grant shall be 4 years.

“(2) DISBURSEMENT.—To the extent amounts are provided in appropriation Acts for such grant, the Director shall disburse the amount of the grant made under subsection (a) on an annual basis.”.

The SPEAKER pro tempore. Pursuant to the rule, the gentleman from California (Mr. ROUDA) and the gentleman from Arizona (Mr. GOSAR) each will control 20 minutes.

The Chair recognizes the gentleman from California.

#### GENERAL LEAVE

Mr. ROUDA. Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days in which to revise and extend their remarks and include extraneous material on this measure.

The SPEAKER pro tempore. Is there objection to the request of the gentleman from California?

There was no objection.

Mr. ROUDA. Mr. Speaker, I yield myself such time as I may consume.

Mr. Speaker, I am proud to support this bipartisan legislation that will make technical changes to the reauthorization of the Office of National Drug Control Policy included in last year's SUPPORT Act.

As we all know, we are in the midst of a substance use disorder epidemic fueled by the proliferation of opioids, exacerbated by synthetic opioids like fentanyl, and increased use of methamphetamines, among other threats.

This year, Americans will lose close to 70,000 friends and family and loved ones due to drug overdoses. More Americans are now dying annually due to overdose than at the height of the AIDS crisis or during the entire Vietnam war.

No community is unaffected by the crisis. In my home of Orange County, California, drug and alcohol overdose deaths have increased by 82 percent since 2000. Across our country, our constituents are asking us to advance solutions to address this epidemic.

Last year, Congress passed and President Trump signed the SUPPORT for Patients and Communities Act, a wide-ranging, bipartisan bill aimed at addressing treatment, prevention, recovery, and enforcement.

The SUPPORT Act represents an important step in the right direction to reverse the tide of overdose deaths. The SUPPORT Act included provisions to reauthorize and reform the Office of National Drug Control Policy, a component of the Executive Office of the President.

ONDPC plays a critical role in overseeing the Federal Government's drug control efforts. However, there were several technical issues in the SUPPORT Act that must be corrected to ensure that the office can properly carry out its duties as Congress intended and improve the Federal Government's response to this crisis.

The ONDCP Technical Corrections Act of 2019 would ensure the integrity of the performance measurement system, help ONDCP hire the best people to address the addiction crisis, and improve the effectiveness of grant programs. These corrections would help ONDCP's efficient and effective execution of its mission: preventing, combating, and treating the effects of drug proliferation throughout our Nation.

I thank the gentleman from North Carolina (Mr. MEADOWS), my fellow Member, for joining me in introducing this bill and the committee staff on both sides of the aisle for working diligently to develop and advance it. I look forward to the House of Representatives passing this bill today.

There is much more to be done to address the addiction crisis, and I look forward to continued work with all of my colleagues on this important issue.

Mr. Speaker, I reserve the balance of my time.

HOUSE OF REPRESENTATIVES,  
COMMITTEE ON ENERGY AND COMMERCE,  
Washington, DC, October 15, 2019.  
Hon. ELLJAH E. CUMMINGS,  
Chair, Committee on Oversight and Reform,  
Washington, DC.

DEAR CHAIRMAN CUMMINGS: I write concerning H.R. 3889, the "ONDCP Technical Corrections Act of 2019," which was additionally referred to the Committee on Energy and Commerce.

In recognition of the desire to expedite consideration of H.R. 3889, the Committee on Energy and Commerce agrees to waive formal consideration of the bill as to provisions that fall within the Rule X jurisdiction of the Committee on Energy and Commerce. The Committee takes this action with the mutual understanding that we do not waive any jurisdiction over the subject matter contained in this or similar legislation, and that the Committee will be appropriately consulted and involved as this bill or similar legislation moves forward so that we may address any remaining issues within our jurisdiction. I also request that you support my request to name members of the Committee on Energy and Commerce to any conference committee to consider such provisions.

Finally, I would appreciate the inclusion of this letter into the Congressional Record during floor consideration of H.R. 3889.

Sincerely,

FRANK PALLONE, Jr.,  
Chairman.

HOUSE OF REPRESENTATIVES,  
COMMITTEE ON OVERSIGHT AND REFORM,  
Washington, DC, October 16, 2019.  
Hon. FRANK PALLONE, Jr.,  
Chairman, Committee on Energy and Commerce,  
House of Representatives, Washington, DC.

DEAR CHAIRMAN PALLONE: Thank you for your letter regarding H.R. 3889, the ONDCP Technical Corrections Act of 2019. As you know, the bill was referred primarily to the Committee on Oversight and Reform with an additional referral to the Committee on Energy and Commerce.

I thank you for allowing the Committee on Energy and Commerce to be discharged from further consideration of the bill to expedite floor consideration. This discharge in no way affects your jurisdiction over the subject matter of the bill, and it will not serve as precedent for future referrals. In addition, should a conference on the bill be necessary, I would support your request to have the Committee on Energy and Commerce represented on the conference committee.

I would be pleased to include this letter and any response in the Congressional Record during floor consideration to memorialize our understanding.

Sincerely,

ELLJAH E. CUMMINGS,  
Chairman.

Mr. GOSAR. Mr. Speaker, I yield myself such time as I may consume.

Mr. Speaker, I rise in support of H.R. 3889, the ONDCP Technical Corrections Act of 2019. Simply, this bill makes technical amendments to a law we passed last Congress.

We moved quickly last Congress to reauthorize the Office of National Drug Control Policy. The reauthorization was drafted to reinvigorate the office and give the Trump administration additional authorities to address the opioid crisis.

Last Congress, the Committee on Oversight and Reform worked across party lines on a policy solution. President Trump appointed Jim Carroll to lead that office. The Senate confirmed his nomination earlier this year.

Since then, Director Carroll has twice testified before the Committee on Oversight and Reform about the good work the administration is doing to combat the crisis. This bill will help to further support this administration's good work.

I want to congratulate the gentleman from California (Mr. ROUDA) for his good work on this bill, and I urge my colleagues to support it.

Mr. Speaker, I yield back the balance of my time.

Mr. ROUDA. Mr. Speaker, I yield back the balance of my time.

The SPEAKER pro tempore. The question is on the motion offered by the gentleman from California (Mr. ROUDA) that the House suspend the rules and pass the bill, H.R. 3889, as amended.

The question was taken; and (two-thirds being in the affirmative) the rules were suspended and the bill, as amended, was passed.

A motion to reconsider was laid on the table.

PRESIDENTIAL ALLOWANCE  
MODERNIZATION ACT OF 2019

Mr. ROUDA. Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 1496) to amend the Act of August 25, 1958, commonly known as the "Former Presidents Act of 1958", with respect to the monetary allowance payable to a former President, and for other purposes, as amended.

The Clerk read the title of the bill.

The text of the bill is as follows:

H.R. 1496

*Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,*

SECTION 1. SHORT TITLE.

This Act may be cited as the "Presidential Allowance Modernization Act of 2019".

SEC. 2. AMENDMENTS.

(a) IN GENERAL.—The Act entitled "An Act to provide retirement, clerical assistants, and free mailing privileges to former Presi-

dents of the United States, and for other purposes", approved August 25, 1958 (commonly known as the "Former Presidents Act of 1958") (3 U.S.C. 102 note), is amended—

(1) by striking "That (a) each" and inserting the following:

"SECTION 1. FORMER PRESIDENTS LEAVING OFFICE BEFORE PRESIDENTIAL ALLOWANCE MODERNIZATION ACT OF 2019.

"(a) Each";

(2) by redesignating subsection (g) as section 3 and adjusting the margin accordingly; and

(3) by inserting after section 1, as so designated, the following:

"SEC. 2. FORMER PRESIDENTS LEAVING OFFICE AFTER PRESIDENTIAL ALLOWANCE MODERNIZATION ACT OF 2019.

"(a) ANNUITIES AND ALLOWANCES.—

"(1) ANNUITY.—Each modern former President shall be entitled for the remainder of his or her life to receive from the United States an annuity at the rate of \$200,000 per year, subject to subsections (b)(2) and (c), to be paid by the Secretary of the Treasury.

"(2) ALLOWANCE.—The Administrator of General Services is authorized to provide each modern former President a monetary allowance at the rate of \$200,000 per year, subject to the availability of appropriations and subsections (b)(2), (c), and (d).

"(b) DURATION; FREQUENCY.—

"(1) IN GENERAL.—The annuity and allowance under subsection (a) shall each—

"(A) commence on the day after the date on which an individual becomes a modern former President;

"(B) terminate on the date on which the modern former President dies; and

"(C) be payable on a monthly basis.

"(2) APPOINTIVE OR ELECTIVE POSITIONS.—The annuity and allowance under subsection (a) shall not be payable for any period during which a modern former President holds an appointive or elective position in or under the Federal Government to which is attached a rate of pay other than a nominal rate.

"(c) COST-OF-LIVING INCREASES.—Effective December 1 of each year, each annuity and allowance under subsection (a) that commenced before that date shall be increased by the same percentage by which benefit amounts under title II of the Social Security Act (42 U.S.C. 401 et seq.) are increased, effective as of that date, as a result of a determination under section 215(i) of that Act (42 U.S.C. 415(i)).

"(d) LIMITATION ON MONETARY ALLOWANCE.—

"(1) IN GENERAL.—Notwithstanding any other provision of this section, the monetary allowance payable under subsection (a)(2) to a modern former President for any 12-month period—

"(A) except as provided in subparagraph (B), may not exceed the amount by which—

"(i) the monetary allowance that (but for this subsection) would otherwise be so payable for such 12-month period, exceeds (if at all)

"(ii) the applicable reduction amount for such 12-month period; and

"(B) shall not be less than the amount determined under paragraph (4).

"(2) DEFINITION.—

"(A) IN GENERAL.—For purposes of paragraph (1), the term 'applicable reduction amount' means, with respect to any modern former President and in connection with any 12-month period, the amount by which—

"(i) the sum of—

"(I) the adjusted gross income (as defined in section 62 of the Internal Revenue Code of 1986) of the modern former President for the most recent taxable year for which a tax return is available; and